[Predictive factors of hormonal therapy in breast cancer].
Breast cancer is a hormone-dependent cancer, and the presence of estrogen receptor (ER) and progesterone receptor (PgR) in tumors is used clinically to predict the likelihood of response to hormonal therapies. This review describes the roles of (1) hormone related factors (ER, PgR, phosphorylated ER, ERbeta, aromatase), (2) growth related factors (HER2, Ki67, p53), (3) ER cofactors (AIB1, NcoR1), (4) estrogen dependent genes derived from gene expression profiling (HDAC6, IGFBP4/5), and (5) gene profiling using cDNA microarray. There are, however, considerable methodological difficulties in identifying useful predictive factors but on the basis of current evidence other biomarkers add little additional information. The prospective and multi-centered analyses will be warranted to develop the predictive factors for directing use of these therapies.
Iwase
Hirotaka
H
Department of Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University Graduate School of Medicine.
D001141:Aromatase / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D020411:Oligonucleotide Array Sequence Analysis; D010446:Peptide Fragments / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D001141:Aromatase; D015415:Biomarkers; D019394:Ki-67 Antigen; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C509415:p53 protein (325-355), human